Literature DB >> 20373904

The Adaptive Aerosol Delivery (AAD) technology: Past, present, and future.

John Denyer1, Tony Dyche.   

Abstract

Conventional aerosol delivery systems and the availability of new technologies have led to the development of "intelligent" nebulizers such as the I-neb Adaptive Aerosol Delivery (AAD) System. Based on the AAD technology, the I-neb AAD System has been designed to continuously adapt to changes in the patient's breathing pattern, and to pulse aerosol only during the inspiratory part of the breathing cycle. This eliminates waste of aerosol during exhalation, and creates a foundation for precise aerosol (dose) delivery. To facilitate the delivery of precise metered doses of aerosol to the patient, a unique metering chamber design has been developed. Through the vibrating mesh technology, the metering chamber design, and the AAD Disc function, the aerosol output rate and metered (delivered) dose can be tailored to the demands of the specific drug to be delivered. In the I-neb AAD System, aerosol delivery is guided through two algorithms, one for the Tidal Breathing Mode (TBM), and one for slow and deep inhalations, the Target Inhalation Mode (TIM). The aim of TIM is to reduce the treatment time by increasing the total inhalation time per minute, and to increase lung deposition by reducing impaction in the upper airways through slow and deep inhalations. A key feature of the AAD technology is the patient feedback mechanisms that are provided to guide the patient on delivery performance. These feedback signals, which include visual, audible, and tactile forms, are configured in a feedback cascade that leads to a high level of compliance with the use of the I-neb AAD System. The I-neb Insight and the Patient Logging System facilitate a further degree of sophistication to the feedback mechanisms, by providing information on long term adherence and compliance data. These can be assessed by patients and clinicians via a Web-based delivery of information in the form of customized graphical analyses.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20373904      PMCID: PMC3116630          DOI: 10.1089/jamp.2009.0791

Source DB:  PubMed          Journal:  J Aerosol Med Pulm Drug Deliv        ISSN: 1941-2711            Impact factor:   2.849


  13 in total

1.  Adaptive Aerosol Delivery (AAD) technology.

Authors:  J Denyer; K Nikander; N J Smith
Journal:  Expert Opin Drug Deliv       Date:  2004-11       Impact factor: 6.648

2.  History of aerosol therapy: liquid nebulization to MDIs to DPIs.

Authors:  Paula J Anderson
Journal:  Respir Care       Date:  2005-09       Impact factor: 2.258

3.  Adherence to nebulised antibiotics in cystic fibrosis.

Authors:  Gary Latchford; Alistair Duff; Joanne Quinn; Steve Conway; Mark Conner
Journal:  Patient Educ Couns       Date:  2008-10-25

Review 4.  In vitro characterization of the I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Lucy E A Hardaker; Ross H M Hatley
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

5.  Evaluation of patient-reported outcomes and quality of life with the I-neb AAD system in patients with chronic obstructive pulmonary disease.

Authors:  Nicola Goodman; Mike Morgan; Kurt Nikander; Sarah Hinch; Steven Coughlin
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

6.  Evaluation of the Target Inhalation Mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis.

Authors:  John Denyer; Ivan Prince; Emma Dixon; Penny Agent; Jennifer Pryor; Margaret Hodson
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

7.  The Adaptive Aerosol Delivery system in a telehealth setting: patient acceptance, performance and feasibility.

Authors:  Kurt Nikander; John Denyer; Mary Dodd; Tony Dyche; Kevin Webb; Peter Weller; David Stableforth
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

8.  Parents' adherence with nebulizer treatment of their children when using an adaptive aerosol delivery (AAD) system.

Authors:  Kurt Nikander; Lars Arheden; John Denyer; Nicolas Cobos
Journal:  J Aerosol Med       Date:  2003

9.  Aerosol delivery devices in the treatment of asthma.

Authors:  Dean R Hess
Journal:  Respir Care       Date:  2008-06       Impact factor: 2.258

10.  THE effects of tonic lung inflation on ventilation in the American bullfrog Rana catesbeiana Shaw.

Authors:  C E Sanders; W K Milsom
Journal:  J Exp Biol       Date:  2001-08       Impact factor: 3.312

View more
  11 in total

1.  Intelligent nebulizers in the age of the Internet: The I-neb Adaptive Aerosol Delivery (AAD) system.

Authors:  Rajiv Dhand
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2010-04       Impact factor: 2.849

2.  Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension.

Authors:  Manuel J Richter; Hossein A Ghofrani; Robert Voswinckel; Werner Seeger; Richard Schulz; Frank Reichenberger; Henning Gall
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 3.  Devices for Improved Delivery of Nebulized Pharmaceutical Aerosols to the Lungs.

Authors:  Worth Longest; Benjamin Spence; Michael Hindle
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2019-07-09       Impact factor: 2.849

4.  Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems.

Authors:  Susanne R Youngren-Ortiz; Nishant S Gandhi; Laura España-Serrano; Mahavir B Chougule
Journal:  Kona       Date:  2015-09-30       Impact factor: 2.897

Review 5.  Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.

Authors:  Chantal Darquenne; John S Fleming; Ira Katz; Andrew R Martin; Jeffry Schroeter; Omar S Usmani; Jose Venegas; Otmar Schmid
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-02-01       Impact factor: 2.849

6.  Inhaled iloprost for patients with precapillary pulmonary hypertension and right-side heart failure.

Authors:  Amadea M Martischnig; Alexander Tichy; Mariam Nikfardjam; Gottfried Heinz; Irene M Lang; Diana Bonderman
Journal:  J Card Fail       Date:  2011-07-08       Impact factor: 5.712

7.  Variability in delivered dose and respirable delivered dose from nebulizers: are current regulatory testing guidelines sufficient to produce meaningful information?

Authors:  Ross Hm Hatley; Sarah M Byrne
Journal:  Med Devices (Auckl)       Date:  2017-02-01

Review 8.  Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.

Authors:  Diego J Maselli; Holly Keyt; Marcos I Restrepo
Journal:  Int J Mol Sci       Date:  2017-05-16       Impact factor: 5.923

9.  Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.

Authors:  Charles S Haworth; Juliet E Foweraker; Peter Wilkinson; Robert F Kenyon; Diana Bilton
Journal:  Am J Respir Crit Care Med       Date:  2014-04-15       Impact factor: 21.405

Review 10.  Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.

Authors:  Carlos Cruz-Teran; Karthik Tiruthani; Morgan McSweeney; Alice Ma; Raymond Pickles; Samuel K Lai
Journal:  Adv Drug Deliv Rev       Date:  2020-12-09       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.